Welcome to our dedicated page for Inozyme Pharma SEC filings (Ticker: INZY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Inozyme Pharma Inc. filings document the company’s transition from a Nasdaq-listed clinical-stage biotechnology issuer to an acquired company. The filing record includes Form 8-K material-event disclosures for the completed BioMarin acquisition, related termination of the employee stock purchase plan, and capital-structure matters involving Inozyme common stock.
Subsequent corporate-status filings include Nasdaq’s Form 25 notification removing the common stock from listing and registration and Inozyme’s Form 15 certification to terminate or suspend Exchange Act reporting obligations. Earlier disclosures also cover shareholder voting matters, operating and financial results, governance, and clinical or regulatory information tied to INZ-701 and rare-disease development.
Inozyme Pharma COO Matthew Winton acquired 14,355 shares of common stock on June 25, 2025, through the company's Employee Stock Purchase Plan (ESPP). The shares were purchased at $0.74 per share, representing 85% of the closing price on April 1, 2025, the first day of the purchase period.
Following this transaction, Winton's direct beneficial ownership increased to 21,743 shares. The purchase was made during the ESPP period running from April 1, 2025, through June 25, 2025.
- Transaction Type: Stock Purchase through ESPP
- Purchase Price: $0.74 per share (15% discount)
- Ownership Form: Direct
- Filing Status: Individual filing
This insider purchase through the ESPP demonstrates continued participation in company equity programs by key executive leadership.
Insider Trading Alert: Douglas A. Treco, CEO & Chairman of Inozyme Pharma (NASDAQ: INZY), acquired 2,815 shares of common stock on June 25, 2025, through the company's Employee Stock Purchase Plan (ESPP).
Key Transaction Details:
- Purchase price: $0.74 per share (85% of closing price on April 1, 2025)
- Total shares owned after transaction: 43,861 shares
- Ownership type: Direct
- ESPP purchase period: April 1, 2025 - June 25, 2025
The transaction was executed under the company's 2020 ESPP, which allows employees to purchase company stock at a discount. This insider purchase by the CEO demonstrates continued alignment with shareholder interests and potential confidence in the company's prospects.
Inozyme Pharma (INZY) SVP, CFO & Head of BD Sanjay Subramanian reported the acquisition of 6,813 shares of common stock on June 25, 2025, through the company's Employee Stock Purchase Plan (ESPP).
Key transaction details:
- Purchase price: $0.74 per share (85% of closing price on April 1, 2025)
- ESPP purchase period: April 1, 2025 - June 25, 2025
- Total shares owned after transaction: 39,701 shares
- Ownership form: Direct
This insider purchase through the ESPP demonstrates continued participation in company equity programs by a key executive officer. The transaction was executed under the company's 2020 Employee Stock Purchase Plan, which allows employees to purchase shares at a discount to market price.
Inozyme Pharma has announced the postponement of its 2025 Annual Meeting of Stockholders, originally scheduled for June 25, 2025, due to a pending acquisition by BioMarin Pharmaceutical. If the acquisition completes, no public stockholder annual meeting will be held. If it doesn't proceed, the Board will reschedule the meeting with a new record date.
Key Company Profile:
- Clinical-stage biopharmaceutical company with ~50 Boston-based employees
- Focuses on PPi-Adenosine Pathway therapeutics for bone health and blood vessel function
- Lead therapy INZ-701, an ENPP1 Fc fusion protein, is in late-stage clinical trials
- Target conditions include ENPP1 Deficiency, ABCC6 Deficiency, and calciphylaxis
The filing includes detailed information about the tender offer process and directs stockholders to review important acquisition-related documents filed with the SEC by both companies. Materials are available on the SEC website and both companies' respective websites.
Inozyme Pharma, Inc. (Nasdaq: INZY) filed a Form 8-K on June 20, 2025 to disclose that it has postponed its 2025 Annual Meeting of Stockholders in light of the previously announced acquisition by BioMarin Pharmaceutical Inc. The decision is detailed in a press release attached as Exhibit 99.1; an Inline XBRL cover-page file is included as Exhibit 104.
The report stresses that the tender-offer process is governed by documents already on file with the SEC: BioMarin and Incline Merger Sub’s Schedule TO (Offer to Purchase, Letter of Transmittal and related materials) and Inozyme’s Schedule 14D-9 Solicitation/Recommendation Statement. Investors are urged to review these materials, which are available without charge on www.sec.gov and the companies’ investor-relations websites.
No financial statements, operating metrics or earnings information accompany this current report. The filing is limited to the postponement notice and related procedural information regarding the pending transaction.